Fueled by the ecosystem’s rich academic, research, industry, state and health system resources, biopharmaceutical developers and innovators support thousands of Georgia jobs and improve the lives of countless patients worldwide.
On June 20, we will explore the latest in biopharmaceutical innovation and strategic considerations that impact drug development. Leading the conversation during this upcoming quarterly member meeting will be: Dennis Liotta, Ph.D., Executive Director, Emory Institute for Drug Development, Neha Shah, M. Pharm., Ph.D. and Scientist-III (Product Development) for Recro Gainesville and Alan Smith, Ph.D., Co-Founder, 4P Therapeutics.
More specifically, the panel will discuss ways precision medicine is impacting drug development and strategies for overcoming challenges in study management, etc.
Borrowed from his Emory Winship Cancer Center bio, Dr. Liotta’s research has focused on the discovery and development of antiviral, anticancer and anti-inflammatory therapeutic agents. He is one of the leaders of the Emory research team that discovered the antiviral drug, Emtriva (emtricitabine), which was approved for treating HIV in July 2003 and is now used by more than 90 percent of HIV/AIDS patients in the United States, and by thousands more around the globe.
Mr. Smith has led major research and development programs with pharmaceutical companies such as Eli Lilly, Amylin, Hospira, Elan, and Novartis. He spent 12 years growing Georgia based Altea Therapeutics’ multidisciplinary drug delivery research and development organization.
With expertise in drug product development from concept to clinic, Dr. Shah brings over 10 years of industry experience. She currently leads and provides guidance in the area of product development, clinical manufacturing and technical transfer for Recro’s clients.
Join us June 20 from 7:30 a.m. – 9:00 a.m. at Upstairs Atlanta, 525 Bishop Street NW, Atlanta, GA 30318. Register here.